Ideaya Biosciences Inc (IDYA)

Jan 12, 2025, 12:00 PM EST - 6 days ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

Dec 29, 2024, 6:00 AM EST - 20 days ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Dec 27, 2024, 6:00 AM EST - 22 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2024, 6:00 AM EST - 4 weeks ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Dec 16, 2024, 6:00 AM EST - 4 weeks ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

Dec 11, 2024, 6:00 AM EST - 5 weeks ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

Dec 10, 2024, 6:00 AM EST - 5 weeks ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Dec 9, 2024, 6:00 AM EST - 5 weeks ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

Dec 4, 2024, 2:00 PM EST - 6 weeks ago

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 2, 2024, 6:00 AM EST - 6 weeks ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

Nov 18, 2024, 6:00 AM EST - 2 months ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

Nov 12, 2024, 6:00 AM EST - 2 months ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

Nov 11, 2024, 6:00 AM EST - 2 months ago

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Nov 11, 2024, 6:00 AM EST - 2 months ago

Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Nov 4, 2024, 6:00 AM EST - 2 months ago

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 28, 2024, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

Oct 25, 2024, 6:00 AM EDT - 3 months ago

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Oct 4, 2024, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

Sep 23, 2024, 10:07 AM EDT - 4 months ago

Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate

Sep 23, 2024, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

Sep 22, 2024, 9:00 AM EDT - 4 months ago

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

Sep 20, 2024, 12:45 PM EDT - 4 months ago

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 18, 2024, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Aug 26, 2024, 6:00 AM EDT - 5 months ago

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 6:00 AM EDT - 5 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:48 PM EDT - 6 months ago

Generational Group Advises Schuylkill Haven Casket Company and Columbia Caskets Corp. in its sale to Victoriaville & Co.

FNA

Jul 31, 2024, 6:00 AM EDT - 6 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Jul 31, 2024, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

Jul 29, 2024, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

Jul 11, 2024, 4:05 PM EDT - 6 months ago

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 9, 2024, 10:26 PM EDT - 6 months ago

IDEAYA Announces Pricing of Public Offering

Jul 9, 2024, 4:08 PM EDT - 6 months ago

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jul 8, 2024, 1:05 PM EDT - 6 months ago

IDEAYA Biosciences Soars on Cancer Drug Study Results

Jul 8, 2024, 12:31 PM EDT - 6 months ago

IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer

Jul 8, 2024, 6:00 AM EDT - 6 months ago

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

Jul 5, 2024, 4:05 PM EDT - 7 months ago

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

Jun 25, 2024, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

Jun 24, 2024, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

Jun 3, 2024, 6:00 AM EDT - 8 months ago

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

May 29, 2024, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events

May 28, 2024, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development

May 23, 2024, 5:05 PM EDT - 8 months ago

IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma

May 7, 2024, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event

Apr 24, 2024, 10:05 AM EDT - 9 months ago

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

Apr 22, 2024, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

Apr 1, 2024, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

Mar 12, 2024, 6:00 AM EDT - 11 months ago

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Mar 4, 2024, 6:00 AM EST - 11 months ago

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

Feb 20, 2024, 6:00 AM EST - 11 months ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update